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Abstract
Background: For selected patients with severe emphysema, 
bronchoscopic lung volume reduction with endobronchial 
valves (EBV) is recognized as an additional treatment option. 
In most trials investigating EBV treatment, patients with a 
very low diffusing capacity (DLCO) were excluded from par-
ticipation. Objectives: Our goal was to investigate whether 
EBV treatment in patients with emphysema with a very low 
DLCO is safe and effective. Methods: This was a single-center 
retrospective analysis including patients with emphysema 
and a DLCO ≤20%pred who underwent EBV treatment. Fol-
low-up was performed 6 months post-treatment. Outcome 
parameters were compared to a historical matched control 
group (DLCO > 20%pred, matched for sex, age, forced expira-
tory volume in 1 s [FEV1], and residual volume [RV]). Results: 
Twenty patients (80% female, 64 ± 6 years, FEV1 26 ± 6%pred, 
RV 233 ± 45%pred, DLCO 18 ± 1.6%pred) underwent EBV 
treatment. At 6 months follow-up, we found a statistically 
significant improvement in FEV1 (0.08 ± 0.12 L), RV (–0.45 ± 
0.95 L), 6-min walking distance (38 ± 65 m), and St. George’s 
Respiratory Questionnaire (–12 ± 13 points). With the excep-
tion of FEV1, all exceeded the minimal clinically important 
difference. The most common serious adverse event was a 
pneumothorax requiring intervention (15%). There were no 
significant differences in outcome compared to the DLCO  
> 20%pred control group. Conclusions: In this single-center 
retrospective analysis, we showed statistically significant 
and clinically relevant improvements in lung function, exer-
cise capacity, and quality of life up to 6 months after EBV 
treatment in emphysema patients with a DLCO ≤20% (14–
20%) of predicted with no increased risk of serious adverse 
events. © 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
In advanced chronic obstructive pulmonary disease 
(COPD), breathlessness, impaired exercise capacity, and 
poor quality of life are common despite optimal standard 
therapy [1]. For selected patients with advanced COPD, 
bronchoscopic lung volume reduction with endobron-
This article is licensed under the Creative Commons Attribution-
NonCommercial-NoDerivatives 4.0 International License (CC BY-
NC-ND) (http://www.karger.com/Services/OpenAccessLicense). 
Usage and distribution for commercial purposes as well as any dis-





chial valves (EBV) is recognized as an additional treat-
ment option [2]. Prerequisites for this treatment are the 
presence of emphysema, severe hyperinflation, and ab-
sence of collateral ventilation between the target lobe and 
ipsilateral lobe(s) [3]. EBV treatment has emerged in re-
cent years as a less invasive alternative for lung volume 
reduction surgery and has been shown to improve lung 
function, exercise capacity, and quality of life [4–8].
In most research investigating EBV treatment, pa-
tients with a very low diffusing capacity of the lungs for 
carbon monoxide (DLCO) were excluded from participat-
ing. This is mostly due to the results of the National Em-
physema Treatment Trial (NETT), a large international 
multicenter trial comparing lung volume reduction to 
standard of care, where a subgroup of high-risk patients 
was identified with an increased postoperative mortality 
rate [9, 10]. These high-risk patients were defined by hav-
ing a forced expiratory volume in 1 s (FEV1) of 20% or 
less of the predicted value combined with either a homo-
geneous distribution of emphysema or a DLCO of ≤20% 
of predicted (%pred). However, a recent retrospective tri-
al investigating lung volume reduction surgery in patients 
with a DLCO of < 20%pred showed positive effects of treat-
ment with no increased mortality rate (90-day mortality 
0%) [11].
To our knowledge, no study evaluating outcomes in 
patients with a very low DLCO undergoing EBV-treat-
ment has been published so far. Our goal was to investi-
gate whether patients with COPD and a very low DLCO 
have the same clinical benefits as patients with a DLCO 
above 20%pred and whether these patients are at in-
creased risk of serious adverse events (SAEs). Further-
more, in the group of patients with a very low DLCO, we 
performed subanalyses for multiple patient characteris-
tics relating to reduced oxygen uptake and emphysema 
distribution to assess whether these were associated with 
differences in outcome of EBV treatment.
Material and Methods
Study Design and Population
This was a single-center retrospective analysis including pa-
tients with COPD and a DLCO ≤20%pred who underwent bron-
choscopic lung volume reduction with EBV at our hospital be-
tween April 2016 and October 2018. All patients with a DLCO 
≤20%pred who were treated in our hospital and registered in the 
BREATH-NL Registry (NCT02815683) or participated in a clini-
cal trial (NCT02022683) were included. A historical control group 
of patients treated in our hospital with a DLCO ≥20%pred was se-
lected from the BREATH-NL Registry. These control patients 
were matched for sex, age, FEV1, and residual volume (RV). Dur-
ing the selection process, all outcome parameters were blinded. All 
subjects signed informed consent.
Measurements
Post-bronchodilator spirometry, body plethysmography, and 
diffusion capacity were measured using the Jaeger MasterScreenTM 
(CareFusion, Germany) and were performed according to the 
ATS/ERS guidelines using the reference values from the European 
Community for Coal and Steel [12–14]. Spirometry and body 
plethysmography were performed at baseline and 6 months after 
treatment. The 6-min walking test was performed at baseline and 
6 months and done in accordance with ATS recommendations 
[15]. The St. George’s Respiratory Questionnaire (SGRQ) was used 
to measure health-related quality of life [16] and was obtained at 
baseline and 6 months follow-up. Arterial blood gas analysis, high-
resolution CT scan, quantitative CT analysis, and echocardiogram 
were performed at baseline.
Treatment
All bronchoscopic procedures were performed according to 
current best practice recommendations and all under general an-
esthesia [17]. A Chartis measurement (Chartis®, Pulmonx Corpo-
ration, Redwood City, CA, USA) was performed to assess collat-
eral ventilation between the target lobe and ipsilateral lobe(s). In 
the absence of collateral ventilation, EBV (Zephyr® EBV, Pulmonx 
Corporation, Redwood City, CA, USA) were placed in all segments 
or subsegments of the target lobe.
Data incomplete (n = 1)
SGRQ was not obtained
Data complete (n = 19)
Data complete (n = 14)
No visit (n = 3)
 Intercurrent comorbidities (n = 2)
 Expectoration of EBV (n = 1)
Data incomplete (n = 3)
 SGRQ was not obtained (n = 1)
 Did not feel well enough to 
 perform 6MWT (n = 1)
 No lung function because of a






Treatment with EBV 
(n = 20)





Fig. 1. Study flowchart for patients with a DLCO ≤20%pred. EBV, 
endobronchial valve; SGRQ, St. George’s Respiratory Question-
naire; 6MWT, 6-min walking test.





A patient was considered a responder to treatment if the FEV1, 
RV, 6-min walking distance (6MWD), or SGRQ improved more 
than the minimal clinically important difference (MCID) after 
treatment. The following MCIDs were used: relative change in 
FEV1 ≥12%, a decrease in RV of ≥430 mL, an increase in 6MWD 
of ≥26 m, and a decrease of SGRQ total score of 4 or 7 points [18–
22].
Baseline characteristic Patients with a DLCO
≤20%pred (n = 20)
Patients with a DLCO
>20%pred (historical matched 
control group, n = 20)
Female, n (%) 16 (80) 16 (80)
Age, years 64±6 62±7
Body mass index 21±2.7 23±3.1





























Ratio of RV to TLC, % 68±7 67±5
Carbon monoxide diffusing capacity,  
mmoL/(min×kPa)

















Pre-test oxygen saturation, %





























Target lobe volume, mL
Target lobe voxels below –950 HU, %























Data represented as mean ± SD unless otherwise specified. Heterogeneous emphysema was defined 
as a difference between the target lobe and ipsilateral lobe(s) ≥15% in voxels below –950 HU on HRCT. 
There were no statistically significant differences in baseline characteristics, with the exception of DLCO 
as per study design. FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual vol-
ume; TLC, total lung capacity; SGRQ, St. George’s Respiratory Questionnaire; mMRC, modified Med-
ical Research Counsel; HRCT, high-resolution computed tomography; RUL, right upper lobe; RML, 
right middle lobe; RLL, right lower lobe; LUL, left upper lobe; LLL, left lower lobe.






Subanalyses were performed to assess whether there was a dif-
ference in outcome when patients (with a DLCO ≤20%pred) were 
divided into groups based on baseline partial pressure of oxygen 
in arterial blood on room air (PaO2; ≥8.0 kPa [60 mm Hg] or ˂8.0 
kPa), oxygen saturation (StO2) post 6MWD (≥88 or ˂88%), distri-
bution of emphysema (heterogeneous when difference between 
target and ipsilateral lobe voxels below –950 Hounsfield units on 
high-resolution CT scan ≥15 percentage point, otherwise homo-
geneous), or presence of pulmonary hypertension (right ventricu-
lar peak pressure ˂25 or ≥25 mm Hg on echocardiogram).
Statistics
A Wilcoxon signed ranks test was performed to evaluate the 
difference in lung function, exercise capacity, and quality of life 
between baseline and 6 months follow-up. A Mann-Whitney U 
test was performed for the comparison of outcome parameters be-
tween patients with a DLCO ≤20% vs. DLCO > 20% and also for the 
subgroup analyses. When follow-up data (FEV1, RV, 6MWD, or 
SGRQ) were missing, the patient was considered to be a nonre-
sponder. A p value of < 0.05 was considered statistically significant. 
IBM SPSS Statistics version 23 (IBM, Armonk, NY, USA) was used 
for all analyses.
Results
Twenty patients with advanced COPD and a DLCO 
≤20%pred underwent EBV treatment at our hospital 
(80% female, 58 ± 8 years, FEV1 26 ± 6%pred, RV 233 ± 
45%pred). See study flowchart in Figure 1, and baseline 
characteristics in Table 1. Except for DLCO (p < 0.001), 
there were no significant differences between baseline 
characteristics for the patient group with a DLCO 
≤20%pred and the control group with a DLCO > 20%pred 
(Table 1).
At 6 months follow-up, there was a statistically signif-
icant improvement in all lung function parameters, 
6MWD, and the SGRQ total score compared to baseline 
measurements (Table 2). RV (–0.45 ± 0.95 L), 6MWD (38 
± 65 m), and SGRQ score (–12 ± 13 points) improved 
more than the MCID. This was not the case for FEV1 (0.08 
± 0.12 L). Responder rates at 6 months for the patient 
group with a DLCO ≤20%pred for FEV1, RV, SGRQ (–4 
points), SGRQ (–7 points), and 6MWD were 45, 40, 65, 
50, and 45%, respectively (Fig. 2). There were no statisti-
cally significant differences in lung function parameters, 
6MWD, SGRQ total score, and responder rate between 
the patient group with a DLCO ≤20%pred and the control 
group with a DLCO > 20%pred (Table 2).
No patients died in both the group of patients with a 
DLCO ≤20%pred and the control group during 6 month 
follow-up. In the group of patients with a DLCO ≤20%pred, 
a pneumothorax, for which a chest tube insertion was 
needed, did occur in 3 cases (15%), all within 4 days after 
the procedure. In one of these cases, temporary removal 
of EBV and video-assisted thoracic surgery was addition-
ally performed to resolve the pneumothorax. Three other 
patients had a small pneumothorax not requiring inter-
vention. Three patients developed a COPD exacerbation 
requiring hospital admission (15%). Three patients (15%) 
required additional bronchoscopies for valve replace-
ment. One patient (5%) required removal of all valves be-
Table 2. Change in clinical outcomes 6 months after EBV treatment
Variable Patients with DLCO ≤20%,
6 months FU (n = 17)
Patients with DLCO >20%,
6 months FU (n = 19)
DLCO ≤20 vs.
>20%, p value
ΔFEV1, L (relative increase, %) +0.08±0.12 (14±23)* +0.18±0.16 (28±20) 0.09
ΔFVC, L (relative increase, %) +0.28±0.41 (15±22)* +0.48±0.60 (22±25) 0.40
ΔRV, L (relative increase, %) –0.45±0.95 (–9±18)* –0.74±0.78 (–13±14) 0.50
ΔTLC, L (relative increase, %) –0.25±0.69 (–3±9)* –0.38±0.52 (–5±6) 0.82
ΔRV/TLC, % –5±7* –6±7 0.53
Δ6MWD, m +37±67* +40±83 0.93
ΔSGRQ, points –12±14* –10±16 0.71
Change in lung function, 6MWD and SGRQ total score after EBV treatment for patients with a DLCO ≤20% 
of predicted and patients with a DLCO >20% of predicted. Data represented as mean ± SD. FU, follow-up; FEV1, 
forced expiratory volume in 1 s; FVC, forced vital capacity; RV, residual volume; TLC, total lung capacity; 6MWD, 
6-min walking distance; SGRQ, St. George’s Respiratory Questionnaire. * Significant improvement within the 
DLCO ≤20% group over 6 months (p < 0.05). There were no significant differences between change in outcomes 
6 months after treatments between patients with a DLCO ≤20% and the control group (DLCO >20%).




cause of valve migration and consequently loss of atelec-
tasis due to extensive granulation tissue. No pneumonias 
were reported. No statistically significant differences 
were found for SAEs between the patients with a DLCO 
≤20%pred and the control group (Table 3).
Subgroup analyses for patients with a DLCO ≤20%pred 
divided into groups based on emphysema distribution 
(homogeneous n = 11; heterogeneous n = 5), baseline 
PaO2 (≥8.0 kPa n = 11; ˂ 8.0 kPa n = 5), baseline StO2 after 
6-min walking test (≥88% n = 9; ˂88% n = 7) and pres-
ence of pulmonary hypertension on baseline echocar-
diography (RV peak pressure ˂25 mm Hg n = 6; RV peak 
pressure ≥25 mm Hg n = 10) revealed no statistically sig-
nificant differences for change in lung function parame-
ters, SGRQ scores, and 6MWD at 6 months follow-up, 
with the exception of improvement of forced vital capac-
ity (FVC) in participants without pulmonary hyperten-
sion versus participants with pulmonary hypertension 
(ΔFVC +0.53 ± 0.29 L vs. +0.14 ± 0.42 L, p = 0.045).
Discussion/Conclusion
To our knowledge, this is the first study investigating 
EBV treatment in COPD patients with a very low DLCO, 
that is, 20%pred or lower. We found a statistically signif-
Table 3. Serious adverse events after EBV treatment
Serious adverse event SAEs in patients with
a DLCO ≤20%
(n = 20), n (%)
SAEs in patients with
a DLCO >20%pred





Requiring chest tube drainage 3 (15) 2 (10) 14.7–29.6
Hospital admission for COPD exacerbation 3 (15) 1 (5) 9.8–34.9
Revision bronchoscopy
For replacement or temporal removal of valve(s) 3 (15) 5 (25) 6–20
For permanent removal of valves 1 (5) 1 (5) 1.5–20.5
Pneumonia 0 (0) 2 (10) 0–10
Death 0 (0) 0 (0) 1.5–10
Serious adverse events (SAEs) during 6 months follow-up for patients with a DLCO ≤20% (n = 20) and patients with a DLCO >20%pred 
(n = 20) and reported SAEs in RCTs investigating bronchoscopic lung volume reduction with endobronchial valves with a 3–12-month 







































Fig. 2. Responder rates at 6 months follow-
up for patients with a DLCO ≤20%pred 
(n = 20) and DLCO > 20%pred (n = 20). Re-
sponders were defined as having an im-
provement equal to or greater than the 
minimal clinically important difference for 
FEV1 (≥12%) [18], RV (≥430 mL) [19], 
SGRQ (≥4 points) [21], SGRQ (≥7 points) 
[22], or 6MWD (≥26 m) [20]. There were 
no significant differences in responder 
rates for patients with a DLCO ≤20%pred 
and DLCO > 20%pred. FEV1, forced expira-
tory volume in 1 s; RV, residual volume; 






icant improvement of lung function, 6MWD, and quality 
of life 6 months after EBV treatment. Improvement of 
RV, 6MWD, and SGRQ score were greater than the es-
tablished MCID. Furthermore, there were no statistically 
significant differences in change in lung function, 6MWD, 
SGRQ, and responder rates and SAEs between the low 
DLCO group and the matched control group with a DLCO 
> 20%pred. The most common SAE was a pneumothorax 
requiring chest drainage (15%). Subanalyses of patients 
with a DLCO ≤20%pred divided into groups based on 
baseline characteristics that associate with reduced oxy-
gen uptake and emphysema distribution showed no rel-
evant differences on these outcomes.
There was a trend towards a larger increase in FEV1 in 
patients with a DLCO > 20 vs. ≤20%pred (+0.18 ± 0.16 vs. 
+0.08 ± 0.12, p = 0.08) and a higher responder rate for 
FEV1 in the DLCO > 20%pred group (FEV1 70 vs. 45%, 
p = 0.11), but notably this was not reflected in a greater 
improvement in exercise capacity (6MWD) or quality of 
life (SGRQ). 
A recently published pooled analysis of 6 randomized 
controlled trials investigating EBV treatment (in patients 
with a DLCO ≥20%pred) showed an improvement in 
FEV1 (+21.8% relative increase), RV (–0.58 L), 6MWD 
(+49 m), and SGRQ score (–9.1 points) 3–12 months af-
ter EBV treatment [23]. These results are somewhat bet-
ter than our 6-month follow-up results for patients with 
a DLCO ≤20%pred (FEV1 +16% relative increase, RV 
–0.45 L, 6MWD +38 m, SGRQ –12 points). This may be 
explained by the fact that only patients with heteroge-
neous emphysema were included in 4 of the 6 trials, 
whereas in our study, 65% of patients with a DLCO 
≤20%pred had a homogeneous distribution of emphy-
sema.
The responder rates for FEV1, RV, SGRQ (–4 points), 
and 6MWD for patients with a DLCO ≤20%pred at 6 
months follow-up were 45, 40, 65, and 45%, respectively. 
The responder rates are within the range of responder 
rates published in recent RCTs (FEV1 37–72%, SGRQ 56–
79%, and 6MWD 42–87%) [4, 6–8], with the exception of 
responder rate for RV, which is slightly lower (44–71%). 
It is important to note that our responder rates may be a 
conservative estimate, since all participants with missing 
data were considered to be nonresponders. Furthermore, 
for patients with severe COPD, an MCID of 7 points on 
SGRQ total score has been shown to be more applicable 
to this patient group and treatment [22]. The incidence 
rate of SAEs in the patients group with a DLCO ≤20%pred 
was comparable to recent literature investigating EBV 
treatment (Table 3) [4–8].
In studies investigating EBV treatment, patients with 
a very low DLCO were often excluded. This may not be 
surprising since DLCO has been associated with an in-
creased likelihood of hypoxemia and is a known unfavor-
able prognostic factor in COPD [24, 25]. Furthermore, as 
mentioned in the introduction, the multicenter NETT 
trial investigating lung volume reduction surgery identi-
fied a group of high-risk patients with an FEV1 < 20%pred 
and either a homogeneous distributed emphysema or a 
DLCO ≤20% who had increased 30-day mortality rates 
(16%) [9]. However, patients fulfilling the NETT high risk 
criteria have more recently been demonstrated to be able 
to have good effects from lung volume reduction surgery 
with no increased mortality rate [11, 26]. Furthermore, 
EBV treatment in patients with a FEV1 ≤20%pred has 
been shown to be safe and effective [27, 28], and our study 
shows good results for EBV treatment in patients with a 
DLCO ≤20%pred.
The measurement of DLCO is used as an indication for 
functional gas exchange surface in the lung [29]. In em-
physema, there is loss of gas exchange surface, and an in-
verse linear relation between DLCO and severity of em-
physema on CT has been established [30]. However, in 
COPD, other factors such as ventilation/perfusion (V/Q) 
disturbances, inhomogeneous ventilation, and airway 
obstruction can influence the outcome of the DLCO mea-
surement both negatively and positively [31–33]. The 
measured DLCO for a patient with COPD is therefore like-
ly to be a balance of these factors. COPD is a heteroge-
neous disease, so while in one patient, the outcome of 
DLCO may be mainly due to loss of gas exchange surface, 
in the next patient, airway obstruction and V/Q distur-
bances may be the driving factors influencing DLCO.
We propose that the chance of successful EBV treat-
ment in patients with a very low DLCO is related to the 
balance of factors causing the DLCO to be low. Factors we 
consider favorable in clinical practice are a high destruc-
tion level of the target lobe on chest CT and an FEV1 larg-
er than 20% of the predicted value. Factors we consider 
unfavorable are a homogeneous distribution of emphy-
sema, significant target lobe perfusion, an important hy-
poxemia (i.e., PaO2 < 8.0 kPa or 60 mm Hg), significant 
desaturation during exercise, and pulmonary hyperten-
sion. We take every factor into account, and no single fac-
tor is an absolute contraindication. It is important to note 
that there is no scientific literature to support the use of 
these factors for clinical decision-making.
Our study did have some limitations. First of all, this 
is a retrospective analysis. However, we did include a 
well-matched control group with a significantly higher 




DLCO to compare outcome parameters to. Furthermore, 
to prevent selection bias as much as possible, all patients 
with a DLCO ≤20%pred who underwent EBV treatment 
in our hospital were included. Nevertheless, there were 
emphysema patients with a very low DLCO, who were as-
sessed but not accepted for EBV treatment. Another lim-
itation is that our group of patients is relatively small. For 
the subgroup analyses that were performed, the number 
of patients was likely too small to exclude relevant statis-
tically significant differences. Also, the factors for which 
subanalyses were performed are also factors we take into 
account in our clinical decision-making whether or not 
to treat an individual patient. However, since only a mi-
nority of patients with COPD who undergo EBV treat-
ment have a DLCO ≤20%pred, it may be challenging to 
investigate a larger group of patients. Furthermore, there 
is a risk of bias because of missing data. Therefore, as 
mentioned above, with regard to responder rates, we con-
sidered participants to be nonresponders if data was 
missing. Finally, since no measurement of DLCO or arte-
rial blood gas analysis was performed during follow-up, 
no information is available on change in DLCO or gas ex-
change after EBV treatment.
In conclusion, we found statistically significant and 
clinically relevant improvements in lung function, exer-
cise capacity, and quality of life up to 6 months after EBV 
treatment in COPD patients with a DLCO ≤20%pred, 
with no increased risk of SAEs in this single-center retro-
spective analysis. No factors influencing the chance of a 
successful treatment could be identified in this group of 
participants. However, since the investigated subgroups 
were small, it is too soon to draw any definitive conclu-
sions on the latter subject. It would be interesting to in-
vestigate whether long-term follow-up of EBV treatment 
is comparable for COPD patients with and without a very 
low DLCO. Furthermore, future research investigating 
factors influencing the likeliness of successful EBV treat-
ment in COPD patients with a very low DLCO could great-
ly help clinicians in deciding whether or not EBV treat-
ment is suitable for their patient.
Statement of Ethics
All patients signed informed consent and this study was ap-
proved by the Ethics Committee (NCT02815683 and 
NCT02022683).
Disclosure Statement
M.v.D., J.E.H., K.K., N.H.T.T.H., and H.A.M.K. have no con-
flict of interest. D.-J.S. is an investigator, physician advisor, and 
consultant for PulmonX Inc. CA, USA. No funding was received 
for this study.
Author Contributions
M.v.D. contributed to the trial design, analysis of data, prepara-
tion of the “Results” section and tables, and the writing of the man-
uscript and is the guarantor of the manuscript. J.E.H. contributed 
to the analysis of the data and the discussion and revisions of the 
manuscript. K.K. contributed to the discussion and revisions of the 
manuscript. N.H.T.T.H. contributed to the discussion and revi-
sions of the manuscript. H.A.M.K. contributed to the discussion 
and revisions of the manuscript. D.-J.S. contributed to the trial 
design and the discussion and revisions of the manuscript.
References
 1 Janssen DJ, Wouters EF, Spruit MA. Psycho-
social consequences of living with breathless-
ness due to advanced disease. Curr Opin Sup-
port Palliat Care. 2015 Sep; 9(3): 232–7.
 2 Singh D, Agusti A, Anzueto A, Barnes PJ, 
Bourbeau J, Celli BR, et al. Global Strategy for 
the Diagnosis, Management, and Prevention 
of Chronic Obstructive Lung Disease: the 
GOLD science committee report 2019. Eur 
Respir J. 2019 May 18; 53(5):pii: 1900164.
 3 Herth FJ, Slebos DJ, Criner GJ, Valipour A, 
Sciurba F, Shah PL. Endoscopic Lung Volume 
Reduction: An Expert Panel Recommenda-
tion - Update 2019. Respiration. 2019; 97(6): 
548–57.
 4 Criner GJ, Sue R, Wright S, Dransfield M, Ri-
vas-Perez H, Wiese T, et al.; LIBERATE Study 
Group. A Multicenter Randomized Con-
trolled Trial of Zephyr Endobronchial Valve 
Treatment in Heterogeneous Emphysema 
(LIBERATE). Am J Respir Crit Care Med. 
2018 Nov; 198(9): 1151–64.
 5 Davey C, Zoumot Z, Jordan S, McNulty WH, 
Carr DH, Hind MD, et al. Bronchoscopic lung 
volume reduction with endobronchial valves 
for patients with heterogeneous emphysema 
and intact interlobar fissures (the BeLieVeR-
HIFi study): a randomised controlled trial. 
Lancet. 2015 Sep; 386(9998): 1066–73.
 6 Kemp SV, Slebos DJ, Kirk A, Kornaszewska 
M, Carron K, Ek L, et al.; TRANSFORM 
Study Team *. A Multicenter Randomized 
Controlled Trial of Zephyr Endobronchial 
Valve Treatment in Heterogeneous Emphy-
sema (TRANSFORM). Am J Respir Crit Care 
Med. 2017 Dec; 196(12): 1535–43.
 7 Klooster K, ten Hacken NH, Hartman JE, 
Kerstjens HA, van Rikxoort EM, Slebos DJ. 
Endobronchial Valves for Emphysema with-
out Interlobar Collateral Ventilation. N Engl 
J Med. 2015 Dec; 373(24): 2325–35.
 8 Valipour A, Slebos DJ, Herth F, Darwiche 
K, Wagner M, Ficker JH, et al.; IMPACT 
Study Team. Endobronchial Valve Therapy 
in Patients with Homogeneous Emphyse-
ma. Results from the IMPACT Study. Am J 
Respir Crit Care Med. 2016 Nov; 194(9): 
1073–82.
 9 Fishman A, Fessler H, Martinez F, McKenna 
RJ Jr, Naunheim K, Piantadosi S, et al.; Na-
tional Emphysema Treatment Trial Research 
Group. Patients at high risk of death after 
lung-volume-reduction surgery. N Engl J 





10 Fishman A, Martinez F, Naunheim K, Pianta-
dosi S, Wise R, Ries A, et al.; National Emphy-
sema Treatment Trial Research Group. A ran-
domized trial comparing lung-volume-re-
duction surgery with medical therapy for 
severe emphysema. N Engl J Med. 2003 May; 
348(21): 2059–73.
11 Caviezel C, Schaffter N, Schneiter D, Franzen 
D, Inci I, Opitz I, et al. Outcome After Lung 
Volume Reduction Surgery in Patients With 
Severely Impaired Diffusion Capacity. Ann 
Thorac Surg. 2018 Feb; 105(2): 379–85.
12 Miller MR, Hankinson J, Brusasco V, Burgos 
F, Casaburi R, Coates A, et al.; ATS/ERS Task 
Force. Standardisation of spirometry. Eur 
Respir J. 2005 Aug; 26(2): 319–38.
13 Wanger J, Clausen JL, Coates A, Pedersen OF, 
Brusasco V, Burgos F, et al. Standardisation of 
the measurement of lung volumes. Eur Respir 
J. 2005 Sep; 26(3): 511–22.
14 Stocks J, Quanjer PH; Official Statement of 
The European Respiratory Society. Reference 
values for residual volume, functional residu-
al capacity and total lung capacity. ATS 
Workshop on Lung Volume Measurements. 
Eur Respir J. 1995 Mar; 8(3): 492–506.
15 ATS Committee on Proficiency Standards for 
Clinical Pulmonary Function Laboratories. 
ATS statement: guidelines for the six-minute 
walk test. Am J Respir Crit Care Med. 2002 
Jul; 166(1): 111–7.
16 Jones PW, Quirk FH, Baveystock CM, Little-
johns P. A self-complete measure of health 
status for chronic airflow limitation. The St. 
George’s Respiratory Questionnaire. Am Rev 
Respir Dis. 1992 Jun; 145(6): 1321–7.
17 Slebos DJ, Shah PL, Herth FJ, Valipour A. En-
dobronchial Valves for Endoscopic Lung Vol-
ume Reduction: Best Practice Recommenda-
tions from Expert Panel on Endoscopic Lung 
Volume Reduction. Respiration. 2017; 93(2): 
138–50.
18 Donohue JF. Minimal clinically important 
differences in COPD lung function. COPD. 
2005 Mar; 2(1): 111–24.
19 Hartman JE, Ten Hacken NH, Klooster K, 
Boezen HM, de Greef MH, Slebos DJ. The 
minimal important difference for residual 
volume in patients with severe emphysema. 
Eur Respir J. 2012 Nov; 40(5): 1137–41.
20 Puhan MA, Chandra D, Mosenifar Z, Ries A, 
Make B, Hansel NN, et al.; National Emphy-
sema Treatment Trial (NETT) Research 
Group. The minimal important difference of 
exercise tests in severe COPD. Eur Respir J. 
2011 Apr; 37(4): 784–90.
21 Jones PW. St. George’s Respiratory Question-
naire: MCID. COPD. 2005 Mar; 2(1): 75–9.
22 Welling JB, Hartman JE, Ten Hacken NH, 
Klooster K, Slebos DJ. The minimal impor-
tant difference for the St George’s Respiratory 
Questionnaire in patients with severe COPD. 
Eur Respir J. 2015 Dec; 46(6): 1598–604.
23 van Geffen WH, Slebos DJ, Herth FJ, Kemp 
SV, Weder W, Shah PL. Surgical and endo-
scopic interventions that reduce lung volume 
for emphysema: a systemic review and meta-
analysis. Lancet Respir Med. 2019 Apr; 7(4): 
313–24.
24 Boutou AK, Shrikrishna D, Tanner RJ, Smith 
C, Kelly JL, Ward SP, et al. Lung function in-
dices for predicting mortality in COPD. Eur 
Respir J. 2013 Sep; 42(3): 616–25.
25 Mohsenifar Z, Lee SM, Diaz P, Criner G, Sci-
urba F, Ginsburg M, et al. Single-breath dif-
fusing capacity of the lung for carbon monox-
ide: a predictor of PaO2, maximum work rate, 
and walking distance in patients with emphy-
sema. Chest. 2003 May; 123(5): 1394–400.
26 Meyers BF, Yusen RD, Guthrie TJ, Patterson 
GA, Lefrak SS, Davis GE, et al. Results of lung 
volume reduction surgery in patients meeting 
a national emphysema treatment trial high-
risk criterion. J Thorac Cardiovasc Surg. 2004 
Mar; 127(3): 829–35.
27 Darwiche K, Karpf-Wissel R, Eisenmann S, 
Aigner C, Welter S, Zarogoulidis P, et al. 
Bronchoscopic Lung Volume Reduction with 
Endobronchial Valves in Low-FEV1 Patients. 
Respiration. 2016; 92(6): 414–9.
28 Trudzinski FC, Höink AJ, Leppert D, 
Fähndrich S, Wilkens H, Graeter TP, et al. En-
doscopic Lung Volume Reduction Using En-
dobronchial Valves in Patients with Severe 
Emphysema and Very Low FEV1. Respira-
tion. 2016; 92(4): 258–65.
29 Hughes JM, Bates DV. Historical review: the 
carbon monoxide diffusing capacity (DLCO) 
and its membrane (DM) and red cell (Theta.
Vc) components. Respir Physiol Neurobiol. 
2003 Nov; 138(2-3): 115–42.
30 Nambu A, Zach J, Schroeder J, Jin GY, Kim 
SS, Kim YI, et al. Relationships between dif-
fusing capacity for carbon monoxide (DLCO), 
and quantitative computed tomography mea-
surements and visual assessment for chronic 
obstructive pulmonary disease. Eur J Radiol. 
2015 May; 84(5): 980–5.
31 Thompson BR, Kim Prisk G, Peyton P, Pierce 
RJ, Rochford PD. Inhomogeneity of ventila-
tion leads to unpredictable errors in measured 
D(L)CO. Respir Physiol Neurobiol. 2005 Apr; 
146(2-3): 205–14.
32 Prediletto R, Fornai E, Catapano G, Carli C. 
Assessment of the alveolar volume when sam-
pling exhaled gas at different expired volumes 
in the single breath diffusion test. BMC Pulm 
Med. 2007 Dec 19; 7: 18.
33 Graham BL, Mink JT, Cotton DJ. Overesti-
mation of the single-breath carbon monoxide 
diffusing capacity in patients with air-flow 
obstruction. Am Rev Respir Dis. 1984 Mar; 
129(3): 403–8.
